CCL2 and breast carcinoma: The seminal work by Pollard’s laboratory demonstrated that the therapeutic blockade of CCL2-CCR2 axis interrupts the recruitment of inflammatory monocytes and inhibits metastasis in vivo, prolonging the survival of mice bearing breast cancer [95].